LY2119620
(Synonyms: 3-氨基-5-氯-N-环丙基-4-甲基-6-[2-(4-甲基-1-哌嗪基)-2-氧代乙氧基]-噻吩并[2,3-B]吡啶-2-甲酰胺) 目录号 : GC13445A positive allosteric modulator of M2 and M4 mAChRs
Cas No.:886047-22-9
Sample solution is provided at 25 µL, 10mM.
LY2119620 is a selective positive allosteric modulator of M2/M4 receptor [1].
Muscarinic acetylcholine receptors (M1-M5) are G-protein coupled receptors regulating the action of the neurotransmitter ACh and play an important role in smooth muscle control, exocrine gland function, mood and cognition [1].
LY2119620 is a selective positive allosteric modulator of M2/M4 receptor. In [35S]GTPγS-binding experiments, LY2119620 exhibited a modest allosteric agonism of 23.2% and 16.8% at the M2 and M4 receptors, respectively. LY2119620 and ACh binding caused cooperativity factor α of 79.4 and 19.5 for the M4 receptor and the M2 receptor, respectively. The cooperativity between LY2119620 and orthosteric agonists (Iperoxo or Oxo-M) was also observed [1]. M2 receptor simultaneously bound to LY2119620 and iperoxo. LY2119620 exhibited mild negative cooperativity with the inverse agonist NMS and strong positive cooperativity with iperoxo [2]. LY2119620 significantly increased Bmax values without changes in Kd when cooperativity binding of [3H]LY2119620 with mAChR, suggesting a G protein-dependent process [3].
References:
[1]. Croy CH, Schober DA, Xiao H, et al. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol, 2014, 86(1): 106-115.
Kruse AC, Ring AM, Manglik A, et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature, 2013, 504(7478): 101-106.
Schober DA, Croy CH, Xiao H, et al. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites. Mol Pharmacol, 2014, 86(1): 116-123.
Kinase experiment: | [3H]LY2119620 equilibrium binding is achieved by incubating 15 µg membranes, orthosteric ligand (100 µM), and various concentrations of [3H]LY2119620 (0.2 to 60 nM) for 1 hour at 25°C. The specific binding versus time data are fit to a one-site specific binding model, and the Bmax and Kd for the allosteric molecule are calculated for each orthosteric ligand[1]. |
References: [1]. Croy CH, et al. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol. 2014 Jul;86(1):106-15. |
Cas No. | 886047-22-9 | SDF | |
别名 | 3-氨基-5-氯-N-环丙基-4-甲基-6-[2-(4-甲基-1-哌嗪基)-2-氧代乙氧基]-噻吩并[2,3-B]吡啶-2-甲酰胺 | ||
化学名 | 3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]thieno[2,3-b]pyridine-2-carboxamide | ||
Canonical SMILES | CC1=C2C(=C(SC2=NC(=C1Cl)OCC(=O)N3CCN(CC3)C)C(=O)NC4CC4)N | ||
分子式 | C19H24ClN5O3S | 分子量 | 437.94 |
溶解度 | ≥ 21.897mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2834 mL | 11.4171 mL | 22.8342 mL |
5 mM | 0.4567 mL | 2.2834 mL | 4.5668 mL |
10 mM | 0.2283 mL | 1.1417 mL | 2.2834 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet